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A B S T R A C T   
Maintaining adherence to treatment for tuberculosis (TB) is essential if the disease is to be eliminated. As part of 
formative research to develop an intervention to improve adherence, we documented the lived experiences of 
adults receiving anti-TB treatment (ATT) in three UK cities and examined how personal, social, and structural 
circumstances interacted to impact on individuals’ adherence to treatment. Using a topic guide that explored 
social circumstances and experiences of TB care, we conducted in-depth interviews with 18 adults (six women) 
who were being or had been treated for TB (patients) and four adults (all women) who were caring for a friend, 
relative, or partner being treated for TB (caregivers). We analysed transcripts using an adapted framework 
method that classified factors affecting adherence as personal, social, structural, health systems, or treatment- 
related. Eleven of 18 patients were born outside the UK (in South, Central, and East Asia, and Eastern and 
Southern Africa); among the seven who were UK-born, four were Black, Asian, or Minority Ethnic and three were 
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White British. TB and its treatment were often disruptive: in addition to debilitating symptoms and side effects of 
ATT, participants faced job insecurity, unstable housing, stigma, social isolation, worsening mental health, and 
damaged relationships. Those who had a strong support network, stable employment, a routine that could easily 
be adapted, a trusting relationship with their TB team, and clear understanding of the need for treatment re-
ported finding it easier to adhere to ATT. Changes in circumstances sometimes had dramatic effects on an in-
dividual’s ability to take ATT; participants described how the impact of certain acute events (e.g., the onset of 
side effects or fatigue, episodes of stigmatisation, loss of income) were amplified by their timing or through their 
interaction with other elements of the individual’s life. We suggest that the dynamic and fluctuating nature of 
these factors necessitates comprehensive and regular review of needs and potential problems, conducted before 
and during ATT; this, coupled with supportive measures that consider (and seek to mitigate) the influence of 
social and structural factors, may help improve adherence.   
1. Introduction 
Elimination of tuberculosis (TB) is a realistic prospect in low TB 
burden countries such as the United Kingdom (UK), where incidence has 
declined from 15 per 100,000 population in 2011 to 8 per 100,000 in 
2019 [1]. Treating TB disease currently requires at least six months of 
daily therapy [2,3]; non-adherence to anti-TB therapy (ATT) worsens 
individual outcomes [4], increases the risk of drug-resistant TB (DR-TB) 
[5,6], and may prolong infectiousness [7]. Optimising outcomes and 
maintaining adherence to treatment are essential if the World Health 
Organization (WHO) ‘pre-elimination’ target of annual incidence <1 per 
100,000 is to be reached [8,9]. 
TB in the UK is predominantly present in people who are migrants 
[10], socioeconomically disadvantaged, or both [11,12]: 74% of people 
who developed TB in England in 2019 were born outside of the UK [13]. 
Many individuals diagnosed with TB in the UK also have so-called ‘social 
risk factors’ (SRFs: drug or alcohol misuse, homelessness, or current or 
previous imprisonment). In 2019, 35% and 23% of people with TB who 
were born in the UK and outside the UK, respectively, had at least one 
SRF [13]. 
Formal adherence support for ATT in the UK is based on a stand-
ardised risk assessment conducted by a specialist TB nurse (usually the 
individual’s case manager) at treatment initiation. Individuals consid-
ered at high risk of non-adherence are offered enhanced case manage-
ment, which can include directly observed therapy (DOT), video- 
observed therapy (VOT), and other forms of practical treatment sup-
port, such as a weekly dosette box [14]. Enhanced case management is 
offered most often to people with SRFs, though individuals without 
recognised SRFs are also at risk of non-adherence: a study of nearly 
13,000 people treated for TB in London found that although the odds of 
non-adherence were highest in those with at least one SRF, they were 
also high in some migrant communities, people who had previously had 
TB, those with pulmonary disease, and those who were aged 16–24 years 
(versus those aged 25–34 years) [15]. Yet the evidence around risk of 
non-adherence is inconclusive: a recent systematic review found that 
adherence to treatment for DR-TB was no different in migrants and non- 
migrants (n = 8 studies, all in high-income countries) [16]. Therefore, to 
focus supportive resources more efficiently on those with the greatest 
need (i.e., those most likely to have difficulty taking treatment), 
screening methods are required that categorise risk of non-adherence by 
considering a wider range of criteria than simply ‘static’ demographics. 
“Non-adherence” is a term that encompasses a spectrum of behav-
iours at various points throughout the patient’s journey and care 
pathway [17]. The WHO’s call for “care and support, [that is] sensitive and 
responsive to patients’ educational, emotional and material needs” [18] re-
flects the increasing prominence of the discussion around patient- 
centred care for TB [19–21], yet the most widely-used form of ATT 
adherence support, DOT, has been criticised by patients as being 
inflexible and paternalistic; critics suggest that it seeks to ‘enforce’ 
treatment-taking, does not promote patient self-management, and fo-
cuses on pill-taking as the defining feature of treatment adherence 
[22–25]. Evidence-based, supportive approaches are needed that can be 
adapted for use in all individuals starting ATT. 
Globally, numerous qualitative studies have explored adherence to 
ATT: a 2007 systematic review by Munro et al. synthesised qualitative 
data from 44 studies and classified the key determinants of adherence 
into four categories: 1) personal factors, including knowledge and beliefs; 
2) structural factors, including poverty, gender, and law; 3) social factors, 
including family, community, and stigma; and 4) health service-related 
factors, including the organisation of care and side effects [26]. How-
ever, assessing these dimensions as distinct, though useful for analysis, 
risks over-simplification, as adherence behaviour is not constant [27] 
and relationships between different dimensions can be dynamic and 
complex [28]. 
Despite these studies, there are few data available to help shape 
evidence-based, supportive approaches for use across the highly diverse 
populations encountered in high-income, low incidence settings 
[29,30]. The small number of qualitative studies reporting on the ex-
periences of individuals with TB in the UK have focused on sub- 
populations living in extreme situations or within specific commu-
nities [31–34]. 
Using an adaptation of the Munro framework that includes greater 
consideration of the dynamic relationships across different levels and 
types of determinants of adherence [29], we conducted in-depth in-
terviews with a diverse group of adults receiving (and caring for those 
on) ATT in three cities in the UK. In this analysis, we examine how in-
dividuals’ experiences of the TB care trajectory, including their 
engagement with the health system and their social networks, influ-
enced how they felt about treatment and their ability to take ATT. We 
use these data to map the relationships between and across factors that 
enabled and impeded adherence to ATT and discuss the implications for 
assessing risk of non-adherence and intervening to improve adherence. 
2. Methods 
Interviews were conducted from April to October 2019 as part of 
formative qualitative research for a study seeking to develop, pilot, and 
evaluate an intervention to support patients taking ATT (“Intervening 
with a Manualised Package to AChieve treatment adherence in people 
with Tuberculosis” [IMPACT]) [35]. Data from qualitative interviews 
were used to shape the form and content of the intervention; all in-
terviews were conducted prior to the implementation of any part of the 
intervention. 
2.1. Sites of data collection 
Formative research was based in four National Health Service (NHS) 
Trusts: two in London and one each in Edinburgh and Southampton; 
recruitment and interviews took place at eight physical sites across the 
three cities. London overall has the highest TB incidence in the country, 
at 18.6 notifications per 100,000 in 2019; [13] the two London Trusts 
involved in the study employed had slightly different modes of care, 
with, for example, a dedicated social care team in one Trust, but not the 
other. Edinburgh (incidence 4.9 per 100,000 in 2018) [36] and South-
ampton (three-year average incidence 11.5 per 100,000) [13] have 
fewer TB patients than London and smaller dedicated services to deal 
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with them. In both Trusts, people with TB are co-managed by the Res-
piratory and Infectious Diseases teams, with two or three specialist TB 
nurses responsible for case management. 
2.2. Sampling and recruitment of participants 
Adults (aged ≥18 years) who were taking or had taken ATT (patients) 
and adults who were caring for or had cared for a friend, relative, or 
partner on ATT (caregivers) were asked to participate; formal inclusion 
and exclusion criteria applied to patients and caregivers are described in 
Supplementary table 1. A purposive sampling approach was adopted; it 
was attempted, throughout, to represent as fully as possible the wide 
range of perspectives and backgrounds within the patient populations at 
each site. Further details of recruitment and consent procedures are 
provided in Appendix 1. 
2.3. Data collection 
Interviews were conducted in confidential settings in hospitals or 
community health centres, often in consultation rooms that also con-
tained a workstation, examination couch, and sink. All interviews were 
conducted in person, by one or two interviewers (one/two of ASK, KK, 
ASKJ, and MD), in English, and with the help of a topic guide (Appen-
dix 1) that covered the following topics: pathways to TB care; treatment 
adherence issues; knowledge and perceptions of TB and treatment; 
adherence to ATT (experiences, enablers, and barriers, and incidence of 
and reasons for non-adherence); social support; and structural and 
health systems issues (interactions with and potential obstacles to care). 
During the interviewing process, the lead interviewer (ASK) confirmed 
with each participant what was being said through short summarisation 
at various points in the interview. 
2.4. Data management and analysis 
Interviews were audio recorded (using an Olympus DS-9500 
[Olympus Corporation, Tokyo, Japan]), securely encrypted, and trans-
ferred to a password-protected computer. Hand-written notes were 
scanned and password protected, and the originals destroyed. Tran-
scripts of interviews were used for analysis after being checked for 
comprehensiveness and completeness. 
Analysis was undertaken by ASK and KK (both of whom cross- 
checked transcripts, cross-checked themes identified, and piloted the 
coding system) in a stepwise manner, using an adapted framework 
analysis method. First, transcripts were read several times; narrative 
profiles of each patient were constructed that included accounts of how 
patients presented themselves and their social networks; their TB diag-
nosis and early experiences of care; and their experiences of being ‘on 
treatment’. Attention was paid to the unique trajectories of individuals 
and how demographic features such as gender, age, ethnicity, and social 
status impacted on pathways to and experiences of care, and the effects 
of TB and ATT on their lives. Second, using a conceptual framework of 
determinants of adherence derived from the systematic review by 
Munro et al. [26] and a previously described scoping review [29], in-
formation was categorised from the profiles into a matrix to compare 
and contrast data on the five key themes (personal, social, structural, 
health systems, and treatment-related; Appendix 1) until theme satu-
ration was reached. Third, the summarised information allowed for the 
creation of separate files for each of the five thematic areas; retrieved 
data segments were supplemented with information from the original 
transcripts and reviewed through a constant comparison method to 
ensure that content and meaning of the themes were consistently 
applied [37]. 
To illustrate the ways in which various factors interacted with one 
another and the mechanisms by which they might influence adherence 
behaviour, relationships between determinants and their potential ef-
fects on an individual’s ability to take ATT were mapped based on 
explicit descriptions by interviewees or through inference by the authors 
after analysis of all interviews. Determinants were categorised as ‘distal’ 
when their influence on adherence behaviour was indirect or mediated 
through intervening factors, or ‘proximal’ when they exerted a more 
direct effect on adherence behaviour. Data were collated and analysed 
using NVivo (v12, QSR International, Doncaster, Australia) and re-
lationships were visually depicted using Vensim (Ventana Systems UK; 
https://www.ventanasystems.co.uk/) and InkScape (https://inkscape. 
org/). 
2.5. Ethical considerations 
This study received approval from the Camberwell St Giles Ethics 
Committee (REC reference 18/LO/1818). Written informed consent was 
obtained from each individual prior to data collection (further details in 
Appendix 1). Pseudonyms are used in the manuscript to humanise ac-
counts and quotes; no information that could potentially identify a 
participant has been included. 
3. Results 
3.1. Participant characteristics 
Interviews were conducted with 18 patients and four caregivers. 
Participants varied widely in age, ethnicity, migration status, level of 
education, profession, knowledge of TB, social support networks, dis-
ease type and severity, experiences of treatment, adherence behaviour, 
and health literacy (Supplementary table 2). 
Ages ranged from 20 to 65 years, but most participants were aged 
20–35 years. The two youngest individuals lived with their parents and 
siblings; others in their 20s and 30s had young children or lived alone. 
Four of the six individuals aged 50 years or older had additional medical 
problems, including cancer and depression. Two-thirds of patients were 
male; all four caregivers were female and had cared for a (male) partner. 
Three patients were White British; four were born in the UK to Black and 
Asian families; and the remaining 11 were migrants, originating from 
South, Central, and East Asia, and Eastern and Southern Africa. 
TB disease severity varied widely and was not necessarily linked to 
age or comorbidities. One of the youngest participants had dissemi-
nated, drug-resistant TB. Two participants had recurrent TB disease, 
needing two courses of ATT in close succession, and another had re- 
started treatment several times (due to non-adherence) and was wait-
ing for surgery to address complications of TB. Other participants pre-
sented with only neck swelling or experienced mild symptoms. 
Participants were at various stages of the treatment journey at the time 
of interview: all had received at least three to four months of treatment 
and four individuals had completed treatment a year or more prior to 
interview. 
Six participants reported high levels of alcohol use, incarceration, 
emergency migration, or homelessness; these individuals had usually 
been identified as ‘high risk’ for non-adherence soon after diagnosis and 
had received some form of treatment support. Some patients who lived 
alone had parents available for support, but others depended on em-
ployers, friends, and, in one case, a landlord. Three participants did not 
report any strong social ties, and described interactions limited to col-
leagues or casual acquaintances. 
3.2. Lived experiences of illness and the care pathway 
3.2.1. Symptom onset and entry into care 
I coughed for probably, like, one, two weeks. …I did some research online, 
it says it might be, you know, even something like lung cancer. And I was 
so scared. I was so scared. I was so scared 
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Zhen, a student in his 20s who lived alone and made several trips to his 
GP and to the Emergency Department before he was diagnosed with TB. 
Experiences early in the treatment journey had lasting effects on 
individuals’ attitude to their illness and engagement with care. Care- 
seeking behaviour and the time taken to enter the TB care pathway 
were influenced by disease severity and could be triggered by a dramatic 
event or acute deterioration in wellbeing, but were also affected by the 
individual’s priorities around their own health, which were sometimes 
displaced by alcohol, insecure housing, or financial commitments; their 
sense of security (i.e., freedom to seek help); and their previous expe-
riences of health care. 
…I started coughing blood. But I didn’t take any notice. I said, ’[inau-
dible], like, leave it’. And my sister she’s a nurse, she noticed that I’m 
losing weight, I’m not eating. She called the ambulance. I got to go to 
[hospital], and they found I had TB. 
Yousuf, a patient in his 30s who consumed large amounts of alcohol and 
had been unwell for some time before he sought care; he had persistent 
problems with adherence and developed DR-TB. 
The time between symptom onset and entry into care was often filled 
with anxiety, and participants described feeling frightened and vulner-
able. Delays sometimes occurred within the health system, through early 
misdiagnosis or extended investigation. Some described losing trust in 
the system if a health care provider (HCP) set expectations that were 
later not met. 
Yeah, so I didn’t take it [the medication] - so that hospital, so eventually I 
moved out, so I wasn’t there no more. And then I had to sign up in a new 
hospital, then start the whole, sort of, treatment again. (…) So I was there 
for about six months without taking no meds and knowing I’ve got TB 
Eunice, a patient in her 20s who had spent time in prison and was living 
in social housing; she described a tenuous relationship with her TB team. 
The way an individual responded to diagnosis was shaped by their 
knowledge and beliefs about TB. These, in turn, were often tied to age, 
culture, class, country of origin, and previous knowledge of the disease. 
For example, some UK-born participants thought of TB as something of 
‘the past’ or associated it with ‘foreigners’, whereas participants from 
high TB burden countries were more likely to consider it a disease of ‘the 
poor’ or of marginalised communities. 
…no one actually in my family, my relatives have ever been diagnosed 
with TB. So I was quite surprised when I was first diagnosed. It’s like, back 
in [South Asian country], the number of reported cases are really high but 
then usually people who suffer from malnutrition, or belonging to, prob-
ably, not so well-to-do families, especially the nutrition part, would get 
affected, and that’s how the illness was probably triggered. 
Rita, a patient in her 30s who moved to the UK to pursue her career. 
3.2.2. Time on treatment 
3.2.2.1. Relationships with immediate family. By the time they started 
ATT, many individuals had depleted physical and emotional resources, 
having been through weeks of illness and investigation. For those whose 
lives were supported by ‘fragile’ infrastructure (tenuous relationships, 
insecure housing, or irregular employment), TB and its treatment were 
sometimes seen as additional burdens (“a hell crisis”) to be shouldered by 
both the patient and their family. 
TB medication being started last year in November I think - that was a 
horrible experience. So he has to leave his job because he couldn’t cope, 
like you know he can’t sleep. Every time he is feeling hungry, so he wants 
to eat something, he is getting up from that, so even I couldn’t sleep 
sometimes. I went upstairs to sleep because I had to sleep - I can’t break 
my sleep - I will get headache because I need to wake up early morning to 
drop my children. 
Jaya speaking about her husband Arif, who resigned from his job a short 
time after starting ATT, making her the family’s main breadwinner. 
The existence of at least one stable, close relationship was important 
in allowing the patient to continue to function, often by relieving them 
of some of their normal responsibilities. 
She’s been a rock, to be honest. She’s… I could just share everything, you 
know what I mean - we don’t hide anything from each other. If I come to 
any consultants or consultations, she comes with me. I prefer that 
because, as I say, I’ve got a bad memory, and she remembers everything. 
Alastair, a patient in his 50s, talking about his wife, Aileen 
I always put on a face to Alastair and my family, and I don’t think they 
realised how depressed I was after the cancer thing. But I know exactly - 
that’s the - you know the worst thing, it’s probably that I know how he’s 
feeling, you know? (…) So that’s helped him as well. I think if he hadn’t 
been through that, I don’t think he’d be coping. 
Aileen, Alastair’s wife, speaking about her previous illness and how it 
helped with her husband’s TB care 
In contrast, participants whose families were overseas felt the 
absence of a local support network acutely, and often felt conflicted 
about how much they could divulge to or ask from family who were far 
away. 
My folks back home didn’t even know that I was diagnosed because I 
didn’t want to upset them. (…) Both of my parents are pretty old, I didn’t 
want to stress them out. 
Rita, who lived alone 
In some cases, the stability provided by relationships worked to 
counter the ‘chaos’ introduced by drugs or alcohol, or the disruption 
caused by multiple hospital visits. However, TB could also put strain on 
existing relationships (e.g., through stigma or changes in power re-
lations), in some cases leading to lasting changes in their character. 
The first week I stayed at the hospital, my mum was like, ‘Don’t come 
home – you’re full of TB, I don’t want you to come home. I don’t want to 
take care of you.’ 
Janella, a patient in her 20s who became tearful recounting this 
experience. 
3.2.2.2. Wider interactions. Relationships beyond the immediate family 
were also important to many participants; for those without partners, 
social groups sometimes formed their primary support network, with 
friends stepping in to help with cooking, shopping, and other day-to-day 
tasks. 
They said to me, ’For the first two weeks, try to have as little contact with 
the general public.’ (…) So I just phoned up one of my mates and said, 
’Get us this from the shop, or whatever, and I’ll sort out the money when 
you come up’. They’d do that. 
Michael, a patient in his 50s who lived alone but had a circle of close, 
supportive friends. 
Interactions with others could also prove difficult, and many patients 
experienced discrimination. Several participants did not disclose their 
diagnosis to their employers, and one even resigned without giving TB as 
a reason, hoping that this would boost his chances of re-employment 
once he recovered. Episodes of discrimination and rejection, even if 
fleeting, sometimes had substantial negative effects on individual’s 
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confidence and sense of identity. 
He offered me a job… He said, ’If you wanna come down, you can stay in 
the caravan on the holiday park and do a bit’. I said, ’I can’t. Got TB’. 
(…) He said, ’You know, no one will touch you - if this gets out, that 
you’ve got it, then most firms… because you’re public liability’. That’s his 
attitude and mentality. If you’re working with other people, then they’ll 
all just, ’Oh, what happens if they catch it?’ 
Michael describing a conversation with a previous employer that made 
him feel suicidal. 
3.2.2.3. Health care professionals. Relationships with HCPs were 
frequently cited as important to patients and caregivers, and the person 
with whom patients had the most contact was usually their TB case 
manager (a nurse) or DOT care worker. Trust in these relationships was 
strengthened by clear, easily accessible two-way communication (e.g., a 
phone number to use out of hours); early demonstrations of confidence 
and competence; a willingness to adapt, including flexibility in 
communication style and acknowledgment of difficult life circum-
stances; a sense of ‘completeness’ of the information received; and 
collaborative decision-making. 
I think the nurses done really, really well here. They are on the ball and 
they get to know you and they know their patients and if someone is going 
to mess around with the tablets. They know who would be committed and 
who wouldn’t, as they do get to know you on that level, which is - I can’t 
fault the team here at all. (…) I’ve still got their numbers. They text, say 
‘How are you?’ 
Naomi, a patient in her 50s who spoke to us a year after completing 
treatment. 
Yeah, because couple of times I was running out the medicine and then I 
had to call her; when I called her she made sure that she got the medicine 
ready for me to come and pick it up. Basically what I think - they know 
what they’re doing. That’s it. 
Aalok, a patient in his 40s, describing his confidence in his TB nurses. 
Interactions with the health service could be challenging for partic-
ipants with serious comorbidities, who sometimes received conflicting 
advice from different specialties, leading to a disjointed experience and 
mistrust. Previous experience of illness sometimes proved useful, 
providing pre-established medication routines or familiarity with the 
health system. However, for those who were unfamiliar with the system 
(usually migrants with no family support), obtaining adequate support 
could be an all-encompassing activity, requiring weeks of correspon-
dence, multiple visits to relevant authorities, and, in some cases, legal 
action. These individuals often had to rely on assistance from members 
of their TB team. 
I don’t blame the doctor or medical system - they are so kind. But I don’t 
understand why they make problem with sickness person. Make hard, 
difficult, complicated. Like, I don’t have energy to do that. I run to - they 
said, “Go to [institution]”. I run to them, they say, “We don’t do this, we 
don’t do that.” (…) Sometimes, when I pop in, they see my face - not 
English - they said, “Oh, we don’t do this, we don’t that.” And they never 
ask, sit down, explain. And I went around, they say, “Go there!” I went 
there, they say, “Go this!” 
Suchin, a patient in her 60s who lived alone and received support from 
the TB social care team to fight her eviction in court 
3.2.2.4. Routines. An established routine or the ability to quickly adopt 
a new routine was described by some participants as ‘the secret’ of 
adherence. This was more difficult for people with relatively 
unstructured lives, in uncertain housing situations, or with serious 
alcohol or drug habits. Some participants found the externally imposed 
routine in hospital to be useful in building a treatment-taking habit. 
Though many found hospital isolating and alienating, it was seen by 
others as a respite from daily life, allowing time for reflection and rest. 
It wasn’t terrible but it gives you a lot of time to think (…) You think you 
are going to lose your life, to be honest, so it’s given me a bigger incentive 
to do more - but I was at my lowest point. 
Naomi, describing the two months she spent in hospital at the start of her 
treatment. 
Even in those who managed to establish robust routines, the number 
of pills and associated side effects could make it difficult to maintain 
regularity. Many individuals developed ‘adjunct’ systems to help keep 
track of the different tablets, such as keeping a written log, organising 
them within a cupboard or box, or setting reminders. 
I think when I was first taking it, I didn’t really fully understand, and some 
of my questions weren’t answered properly. So, I had like a sheet with all 
the medicines that I’m supposed to have - I think that was kind of 
confusing. So what I did when I first got home, was I write it down myself, 
just to make it easy to understand. 
Imran, a patient in his early 20s who lived with his parents and siblings 
Side effects could be debilitating, and for some participants occurred 
daily for several months. Patients often had to rearrange their lives 
around periods when they knew they would be “out of it”. 
“It’s so depressing. You’re having to sit indoors for about four hours 
before - you’re waiting for the person to come round with the tablets, and 
then, you know, you can’t go out. Cos I don’t want to be walking on the 
high street and vomit coming up - people will look at you, and next thing 
you know they get the police on you. So I’m like, ’No, I gotta wait until I 
feel right’. It’s soul-destroying.” 
Michael, speaking about the effects of treatment, side effects, and DOT 
on his daily routine and mental state 
3.3. Dynamic interactions and turning points in adherence behaviour 
Only a few of the processes, relationships, and events discussed 
above, particularly those with a more direct effect on adherence, fit 
cleanly into one of the ‘personal’, ‘social’, ‘structural’, ‘health systems’, 
or ‘treatment-related’ categories, and often the combined effects of two 
or more factors (from different spheres of an individual’s life) were cited 
as influencing adherence-related behaviour. The dynamic nature of 
these interactions was illustrated most clearly when participants 
described changes in circumstances that occurred while they were tak-
ing ATT, and how ‘ripples’ from these events led to sometimes profound 
changes in other aspects of their lives, including their ability to maintain 
a medication habit. Some changes were more predictable, such as a 
latent alcohol habit that became more prominent a few months into 
treatment, or employment that was already unstable but ended after 
starting treatment. Others were less predictable, such as the loss of a 
foundational relationship (due to TB-related or other reasons) or, most 
commonly, fluctuations and deteriorations in mental health. Several 
patients described feeling profoundly anxious and depressed, sometimes 
suicidal, and some described dramatic changes in their personality or a 
loss of identity after starting ATT. 
I was just so afraid that my heart will get something wrong. And [nurse] 
said, ’Do you have anxiety’? Now I started to think about it – probably, 
because of all those kind of issues, I might have some level of anxiety. 
Zhen, who described persistent anxiety about his health several months 
after completing ATT 
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Changes could occur slowly over the course of illness, for example, a 
progressive increase in the amount of alcohol consumed or a gradual 
reduction in mental wellbeing, or could be triggered by specific events 
or phenomena, such as severe side effects (e.g., leading to a sudden 
deterioration in function or hospital admission), pain, fatigue (such that 
someone who was previously able to work had to stop), social or 
physical isolation, episodes of stigmatisation or rejection, eviction, a loss 
of income, or setbacks in treatment. For example, one participant 
experienced worsening fatigue and side effects that meant he could no 
longer work; unemployment then created financial pressure for his 
family and led to the re-emergence of a previous alcohol habit, which 
strained relationships with his wife and children and worsened his 
previous mild cognitive impairment, culminating in him stopping ATT 
entirely. Reduced mental wellbeing, in particular, often put a strain on 
existing relationships, which in turn led to worsening anxiety, isolation, 
and difficulties maintaining a treatment-taking routine. 
When I take the medication, four, five months, my behaviour also is 
changing… Other people are saying, ’What kind of behaviour are you 
doing?’ …I asked one of the colleagues, ’What happened? I don’t know 
what I am doing.’ He told me, ‘Your head is going crazy.’ 
Gopal, a patient in his 30s who described a progressive loss of identity 
and confidence over several months of treatment, to where he was 
reluctant to venture out of the house after dark. 
Using data from all individuals interviewed, Fig. 1 illustrates some of 
the key factors identified and maps their interactions and the mecha-
nisms through which they might affect adherence. Sixteen ‘proximal’ 
characteristics (eight ‘positive’ [top of the figure] and eight ‘negative’ 
[bottom of the figure]) were identified that had a more direct effect on 
an individual’s ability to take treatment: positive characteristics 
included an ability to create and maintain a medication routine, the 
existence of at least one caring or close relationship, and regular 
employment and/or a supportive employer; and negative characteristics 
Fig. 1. Mechanisms* by which personal, social, structural, health systems, and treatment-related factors† influenced individuals’ motivation and ability to take anti- 
TB treatment, based on interviews with 18 patients and four caregivers. ‘Positive’ influences are depicted in the top half of the figure (blue arrows, ‘+’ notation) and 
‘negative’ influences in the bottom half (red arrows,’-‘ notation)*Only key mechanisms have been included for clarity. Additional relationships are undoubtedly 
present but not represented.†Although for some composite factors both the ‘positive’ and ‘negative’ are described explicitly (e.g., good understanding and poor 
understanding), the same holds true for most of the elements included in the figure. For example, the absence of a medication routine was likely to make it more 
difficult to take treatment, and more integrated (i.e., less fragmented) care was likely to make it easier to take treatment. GP: general practitioner; TB: tuberculosis. 
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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included a ‘chaotic’ lifestyle, fragmented care, and severe treatment side 
effects. 
4. Discussion 
In three UK cities, we conducted in-depth interviews with 22 people 
who had taken or cared for someone taking ATT. TB and being ‘on 
treatment’ were often experienced as disruptive: in addition to debili-
tating symptoms, side effects, and stigma, many participants also had to 
balance income loss or reduction, unstable housing, social isolation, 
worsening mental health, and damaged relationships. Those who had a 
strong support network, stable employment, an adaptable routine, a 
trusting relationship with their TB team, and clearly understood the 
need for treatment reported being more easily able to adhere to ATT, 
whereas those with a ‘chaotic’ lifestyle, who were socially isolated, 
experienced severe side effects, or faced structural barriers (such as 
language or recourse to public funds) reported finding it more difficult 
to adhere. 
Based on these data, we frame adherence as a complex, dynamic 
phenomenon that spans a longer timeframe than conventionally exam-
ined. Rather than focusing on static determinants or conceptualising 
adherence as the act of taking or not taking pills as prescribed, we 
suggest the adoption of a relational view (Arakelyan et al., in prepara-
tion) that sees an individual’s life in the context of its complex social and 
structural connections; recognises that health-related behaviour is 
intertwined with other aspects, such as identity, community, and re-
lationships; and allows for the examination of how medicine-taking 
patterns reflect the temporal and socio-spatial fluctuations inherent to 
many individuals’ experience of having TB and receiving care. In 
exploring the mechanisms that may facilitate or impede adherence, we 
demonstrate the extensive potential for non-adherence, even in people 
with so-called ordinary lives. 
Experiences of social exclusion, the detrimental effects of reduced 
social support and stigma, and the importance of routine were important 
themes in our data and were also highlighted by a 2015 study conducted 
among mostly homeless individuals in London [32]. Though our par-
ticipants had fewer ‘established’ risk factors for non-adherence than 
those in the 2015 study, many of the same issues were encountered by 
people with more ‘ordinary’ lives, suggesting that these factors occur 
along a spectrum and defy simplistic binary assessment (as does non- 
adherence itself) [17]. Two studies among African migrants in Shef-
field (Somali adults, 2013) and London (African adults, 2015) discussed 
experiences that were shared by many of our participants, including 
frustration with the diagnostic process in primary care, difficulties in 
maintaining relationships while receiving treatment, the positive effect 
of a supportive social network on adherence, and the toll on mental 
health over the course of treatment [33,34]. Similar themes were also 
identified by a recent critical synthesis of barriers to TB care among 
migrants, which placed ‘relationships’ at the centre of a theoretical 
model of experiences relating to adherence, with ‘cumulative vulnera-
bility’ (the compounding of difficulties faced by migrants across multi-
ple systems), ‘acculturation’ (balancing one’s identity with relationships 
with society), and ‘interpretations of illness’ (individual understanding 
of the disease and the experience) exerting important effects on those 
relationships [38]. 
4.1. Assessment and intervention 
In the absence of robust routine data on adherence [39], there re-
mains a need for consistent, widespread use of contextually modifiable, 
nuanced methods to assess for the likelihood of non-adherence in every 
person starting treatment for TB, as well as socially and culturally sen-
sitive, sustainable approaches to support them through treatment [40]. 
The current TB adherence landscape in the UK is encouraging: the need 
to ensure a “high treatment completion rate” is part of the national TB 
strategy [41]; most NHS Trusts follow the case management model, 
where one specialist TB nurse coordinates an individual’s care from 
diagnosis to discharge [14]; and adherence policy (across conditions) is 
based loosely around the ‘Perceptions and Practicalities’ (PAPA) 
framework, which considers individual motivation and ability, as well as 
a number of intrinsic and extrinsic factors, to specify the ‘minimum in-
gredients’ of adherence support, targeted to the needs of the patient 
[42]. Although DOT remains the mainstay of adherence support in most 
Trusts, VOT [43] is increasingly available, as are medication aids (e.g., 
dosette boxes) and a range of ‘softer’ measures, such as occasional home 
visits or additional phone contact. However, our data suggest that 
despite the emphasis placed by the health system on medicine-taking, 
for many people it remains only one aspect of being ‘on treatment’ 
and may not be prioritised by those trying to balance numerous other 
issues. Some of the major challenges faced by our participants (unstable 
housing and income, restricted access to common resources, and social 
exclusion and isolation) are likely to affect a high proportion of those 
with TB in the UK, given the disproportionate burden of disease in 
people who are migrants, socially deprived, or both [13]. Although some 
TB services (e.g., North Central London) have a dedicated ‘social care’ 
team to help respond to these issues [44], most do not, leading to dis-
parities in the care available to patients in different parts of the country. 
The need for including social support in TB care has been discussed 
for some time, particularly in lower income settings [45], but there is 
limited evidence available around the use of supportive interventions in 
higher income settings upon which to base policy. A systematic review 
of psycho-emotional and socio-economic support interventions for TB 
(which found an association between the use of these interventions and 
better treatment outcomes) included only six studies from high income 
settings published between 1990 and 2015 [46], and in a scoping review 
we found that 70% of the included TB adherence interventions targeted 
only one aspect of adherence, most often a personal or health systems 
component [29]. This is partially reflective of the fragmented disci-
plinary assumptions about when, why, and how people take medicines, 
resulting in the view that knowledge, beliefs, and practices around 
medicine-taking form the crux of adherence (premised on a definition 
that centres on maintaining behaviour that meets HCP recommenda-
tions) [47,48], and that this is the domain most amenable to interven-
tion. This is not restricted to TB: a meta-analysis of theories 
underpinning adherence interventions (n = 124 studies across a range of 
conditions) found that 65% were based around motivation, cognition, or 
beliefs [49], and others have suggested that interventions that do not 
consider wider influences on adherence or that target only one aspect of 
behaviour are likely to be variably effective [50]. 
In considering approaches to intervention, it may help to conceptu-
alise an individual’s life as a complex system [28,51–53], with the 
person at the centre and their actions framed in the context of the 
multiple, relationships with their environment and the people around 
them. This would also allow us to describe the introduction of disease 
and care into that system in energetic terms: complex systems require 
energy to maintain their organisation or ‘order’ [54], and an approach 
that demands the taking of tablets at all costs (i.e., the imposition of 
‘rigid order’) [55] will likely require the input of a large amount of 
energy from the patient, their family, and/or the health system. This is 
particularly the case in patients whose lives are already chaotic, or who 
have less robust support structures. A supportive approach that looks 
more broadly at the ‘system’ (i.e., the patient, their relationships, their 
environment), harnesses existing strengths, identifies vulnerabilities, 
and focuses on improving capability, instead of concentrating in-
terventions primarily on the act of medicine-taking, is likely to be more 
efficient and therefore easier to scale and sustain. 
In addition, if we consider the system to be ‘adaptive’ (that each 
element within the system has the potential to change or evolve based on 
its interactions), every contact between patient and HCP then has the 
potential to be an ‘intervention’. Thus the act of risk assessment, if 
conducted in a way that engages the patient in their own care, could 
itself reduce the risk of non-adherence by improving the individual’s 
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awareness of their vulnerabilities and enabling collaborative strategies 
to be developed that can improve treatment-taking ability. Critically, 
our data suggest that assessments should be repeated at regular intervals 
throughout treatment to account for changes in circumstance or 
capability. 
It is also important to state that many experienced clinicians, 
particularly specialist TB nurses, already work in this patient-centred 
way, though this often requires them to go beyond what the health 
service expects (or supports) them to do. If the universal standard of care 
for people with TB is to be truly “sensitive and responsive” [18] to their 
needs, we cannot rely on the compassion of individual HCPs, but must 
adopt person-centredness throughout the health system [56]. 
4.2. Limitations and strengths 
This study has limitations. Interviews were conducted in health care 
facilities by a medical doctor, which may have influenced the informa-
tion volunteered by participants, though this was not explicitly dis-
cussed with participants, the interviewer was not involved in routine 
care provision, and one other non-clinician was present for most in-
terviews. Despite reassurances of anonymity, participants who were still 
receiving care may have moderated their criticisms of the health service 
out of fear of repercussions. Individuals with DR-TB are likely under- 
represented in our data, though many of the issues we discuss are 
likely to be relevant to them, given the longer and more arduous treat-
ment regimens. Interviews were conducted in English, and some migrant 
experiences will not have been captured; however, many of our partic-
ipants had limited English and several described challenges around 
language and communication. Qualitative data were not linked to 
empirical estimates of adherence in any of the patients interviewed and 
the designation of factors as ‘key determinants’ as well as the relation-
ships between factors depended on self-report by participants and 
interpretation by authors. Our study also has strengths: participants 
were recruited from four NHS Trusts in three cities, reflecting some of 
the variation in care models and resources available in different parts of 
the country; and participants were not recruited from any particular risk 
group, and their common experiences may be closer to those of the 
‘average’ person treated for TB in the UK. 
5. Conclusions 
‘Taking tablets’ is only one aspect of treatment for TB. Supportive 
measures that are truly patient-centred will need to be grounded in a 
deep, contextual understanding of patients’ experiences of, views to-
wards, and behaviours associated with TB and its care. Improving 
adherence among all persons treated for TB, as part of efforts towards 
elimination in low TB incidence countries, will require supportive ap-
proaches that consider not only an individual’s beliefs about TB and 
ATT, but also social and structural circumstances and changes in them 
over time, and look to improve capability, rather than enforce medicine- 
taking. Policy and guidelines need to acknowledge the need for regular 
assessment during treatment if we are to reduce non-adherence to ATT. 
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